Intra-Cellular Therapies, Inc.
ITCIDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001567514
Intra-Cellular Therapies, Inc. was delisted in 2025; its insiders filed their last Form 4 on Apr 2, 2025; 396 institutions reported holding it in 13F filings for Q1 2025, worth $13.6B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 395
- Q1 2025, +11 vs. previous quarter
- 13F value
- $13.6B
- Reported value at the end of Q1 2025
- Superinvestors holding
- 1
- At the end of Q1 2025
Superinvestors holding ITCI, Q1 2025
1 superinvestor reports holding Intra-Cellular Therapies, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
0.3%
Intra-Cellular Therapies, Inc.'s share of the portfolio
- Shares
- 116,588
- Value
- $15.4M
Latest insider trades
Open-market purchases and sales by Intra-Cellular Therapies, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 6, 2024 (view filing) | Dec 4-5 | 2 days | Mates SharonChairman and CEO | SSale | −102.7K | $84.93 | −$8.72M | −8.8%1.07M after | 4 lots10b5-1 |
| Nov 14, 2024 (view filing) | Nov 12-13 | 2 days | Halstead MichaelPresident | SSale | −41.6K | $88.79 | −$3.69M | −100.0%0 after | 5 lots10b5-1 |
| Aug 30, 2024 (view filing) | Aug 29-30 | 1 day | Mates SharonChairman and CEO | SSale | −70.0K | $72.70 | −$5.09M | −6.1%1.07M after | 4 lots10b5-1 |
| Aug 28, 2024 (view filing) | Aug 26-28 | 2 days | Mates SharonChairman and CEO | SSale | −95.9K | $73.54 | −$7.05M | −8.2%1.07M after | 5 lots10b5-1 |
| Aug 23, 2024 (view filing) | Aug 21-23 | 2 days | Mates SharonChairman and CEO | SSale | −121.1K | $75.05 | −$9.09M | −10.2%1.07M after | 7 lots10b5-1 |
| Aug 20, 2024 (view filing) | Aug 16 | 4 days | Neumann MarkEVP, Chief Commercial Officer | SSale | −18.7K | $75.08 | −$1.41M | −38.7%29.7K after | |
| Jun 25, 2024 (view filing) | Jun 24 | 1 day | Riggs Rory BDirector | SSale | −4.46K | $75.57 | −$337.2K | −3.7%116.6K after | |
| Jun 21, 2024 (view filing) | Jun 18 | 3 days | Van Nostrand Robert LDirector | SSale | −20.0K | $75.91 | −$1.52M | −67.4%9.69K after | 2 lots10b5-1 |
| Mar 11, 2024 (view filing) | Mar 7-11 | 4 days | Mates SharonChairman, President & CEO | SSale | −61.3K | $66.07 | −$4.05M | −5.5%1.05M after | 6 lots10b5-1 |
| Mar 11, 2024 (view filing) | Mar 7-11 | 4 days | Hineline Lawrence J.SVP of Finance, CFO | SSale | −23.3K | $66.32 | −$1.54M | −100.0%0 after | 7 lots10b5-1 |
Top 10 13F holders, Q1 2025
The largest institutional positions in Intra-Cellular Therapies, Inc. at the end of Q1 2025; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 9,519,968 | $1.26B | 0.02% | −201,392−2.1% | Reduced |
| BlackRock, Inc. | 8,754,966 | $1.15B | 0.02% | +2,642,243+43.2% | Added |
| Pentwater Capital Management LP | 5,190,000 | $684.7M | 9.55% | +5,190,000 | New |
| HBK Investments L P | 4,385,000 | $578.5M | 10.09% | +4,385,000 | New |
| Norges Bank | 3,579,571 | $472.2M | 0.07% | +366,607+11.4% | Added |
| Davidson Kempner Capital Management LP | 3,485,058 | $459.7M | 6.47% | +3,485,058 | New |
| UBS Oconnor LLC | 3,091,133 | $407.8M | 9.70% | +3,070,849+15,139.3% | Added |
| Farallon Capital Management, L.L.C. | 3,055,000 | $403.0M | 2.17% | +3,055,000 | New |
| FMR LLC | 2,662,273 | $351.2M | 0.02% | −8,414,172−76.0% | Reduced |
| Balyasny Asset Management LLC | 2,257,912 | $297.9M | 0.75% | +2,118,252+1,516.7% | Added |